Bliss GVS Pharma Announces Key Leadership Changes; Mr. Rahul Adakmol Appointed Chief Executive Officer
Bliss GVS Pharma Ltd has announced significant changes in its leadership team, including the appointment of a new Chief Executive Officer and an Additional Director by its Board of Directors. The company confirmed that Mr. Narsimha Shibroor Kamath stepped down from the CEO role while continuing his service as Managing Director, setting the stage for management transitions within the pharmaceutical firm.The changes were approved at a recent Board meeting held on July 3, 2026. Key appointments include the transition of leadership in the executive function and the strengthening of the board structure with a new director joining.
CEO Appointment and Management Transition
Mr. Rahul Adakmol has been appointed as the Chief Executive Officer (CEO) of Bliss GVS Pharma Ltd, effective from July 15, 2026. Mr. Adakmol holds an MBA from the Indian Institute of Management (IIM), Bangalore, and is a seasoned CXO with over 22 years of experience across various aspects of the value chain, including Sales, Marketing, Manufacturing, and Strategy. His career includes senior leadership positions at Bharat Serums and Vaccines, Dr. Reddy's Laboratories, and Reliance Industries.Concurrently, Mr. Narsimha Shibroor Kamath resigned from the position of Chief Executive Officer with effect from the close of business hours on July 14, 2026. He will continue to serve the company in his capacity as Managing Director during this transition period.
The details of these executive changes are summarized below:
| Role | Individual | Effective Date / Resignation Date | Status |
|---|---|---|---|
| Chief Executive Officer (New) | Mr. Rahul Adakmol | July 15, 2026 | Appointed |
| Chief Executive Officer (Outgoing) | Mr. Narsimha Shibroor Kamath | Close of business hours on July 14, 2026 | Resigned |
| Managing Director | Mr. Narsimha Shibroor Kamath | N/A | Continuing role post-resignation |
Appointment of New Director
The Board also approved the appointment of Mr. Santosh Parab as an Additional Director (Non-Executive - Non-Independent) in the company, effective from July 3, 2026.Mr. Parab is a qualified Chartered Accountant and possesses over 35 years of experience spanning audit, taxation, corporate finance, valuation, and financial management. He has previously held roles with State Bank of India, ICICI Bank, Kotak Mahindra Bank, and Bliss GVS Pharma Limited. His expertise lies in business valuations, due diligence, financial restructuring, and corporate advisory services.
Profile details regarding the appointments are provided as follows:
| Position | Individual | Effective Date |
|---|---|---|
| Additional Director (Non-Executive) | Mr. Santosh Parab | July 03, 2026 |
| Chief Executive Officer | Mr. Rahul Adakmol | July 15, 2026 |
BLISSGVS Stock Price Movement
Shares of Bliss GVS Pharma Limited today slipped by 4.29% to settle at ₹504.50. The equity saw a total volume of 634,671 shares traded during the day's session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.